← Stock Trading Canary · All insider profiles
INSIDER PROFILE · UK
Philip Broadley
Non-Executive Director | Non-Executive Director and Chair of the Board of Directors
Profile key: uk|philip broadley
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 3
- Purchases · 24M
- 7
- Average purchase
- £20,947
- Gross purchase value
- £146,626
- Last purchase
- 2026-09-09
- Completed 20D events
- 7.0
- Outcome status
- PASS
Latest company: Lancashire Holdings Limited
Companies: AstraZeneca PLC | Lancashire Holdings Limited
Post-purchase outcomes
Benchmark-relative outcomes are available against FTSE 100.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 7Developing | 100.0% (7/7) | 85.7% (6/7) | +1.8% | +1.4% | -2.4% |
| 20D | 7Developing | 100.0% (7/7) | 42.9% (3/7) | -0.6% | -0.3% | -6.1% |
| 60D | 6Developing | 100.0% (6/6) | 33.3% (2/6) | -4.5% | -3.9% | -17.5% |
| 120D | 5Developing | 100.0% (5/5) | 20.0% (1/5) | -6.3% | -10.1% | -21.6% |
Research patterns
- First purchase in 12M
- 0/5
- Large purchase ≥ €100k
- 0/7
- Cluster buying · 15D
- 0/7
- Buying the dip · ≥20% below prior 52W high
- 1/7
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.